MYCN-targeting MiRNAs Are Predominantly Downregulated During MYCN‑driven Neuroblastoma Tumor Formation
Overview
Authors
Affiliations
MYCN is a transcription factor that plays key roles in both normal development and cancer. In neuroblastoma, MYCN acts as a major oncogenic driver through pleiotropic effects regulated by multiple protein encoding genes as well as microRNAs (miRNAs). MYCN activity is tightly controlled at the level of transcription and protein stability through various mechanisms. Like most genes, MYCN is further controlled by miRNAs, but the full complement of all miRNAs implicated in this process has not been determined through an unbiased approach. To elucidate the role of miRNAs in regulation of MYCN, we thus explored the MYCN-miRNA interactome to establish miRNAs controlling MYCN expression levels. We combined results from an unbiased and genome-wide high-throughput miRNA target reporter screen with miRNA and mRNA expression data from patients and a murine neuroblastoma progression model. We identified 29 miRNAs targeting MYCN, of which 12 miRNAs are inversely correlated with MYCN expression or activity in neuroblastoma tumor tissue. The majority of MYCN-targeting miRNAs in neuroblastoma showed a decrease in expression during murine MYCN-driven neuroblastoma tumor development. Therefore, we provide evidence that MYCN-targeting miRNAs are preferentially downregulated in MYCN-driven neuroblastoma, suggesting that MYCN negatively controls the expression of these miRNAs, to safeguard its expression.
Sheeter D, Garza S, Park H, Benhamou L, Badi N, Espinosa E Cancers (Basel). 2024; 16(8).
PMID: 38672672 PMC: 11048984. DOI: 10.3390/cancers16081590.
Zhai L, Balachandran A, Larkin R, Seneviratne J, Chung S, Lalwani A Int J Mol Sci. 2023; 24(21).
PMID: 37958555 PMC: 10649872. DOI: 10.3390/ijms242115571.
Bagci O, Tumer S, Altungoz O In Vitro Cell Dev Biol Anim. 2023; 59(2):100-108.
PMID: 36800078 DOI: 10.1007/s11626-023-00750-w.
MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment.
Bartolucci D, Montemurro L, Raieli S, Lampis S, Pession A, Hrelia P Cancers (Basel). 2022; 14(18).
PMID: 36139583 PMC: 9496712. DOI: 10.3390/cancers14184421.
De Wyn J, Zimmerman M, Weichert-Leahey N, Nunes C, Cheung B, Abraham B Cancers (Basel). 2021; 13(19).
PMID: 34638267 PMC: 8508013. DOI: 10.3390/cancers13194783.